

Amendments to the Claims

This listing of claims will replace all prior version and listings of claims in the application:

Listing of Claims:

1. (Original): The use of a conjugate comprising a carboxyl group-containing organic compound and albumin for producing a pharmaceutical for modulating a transplantation-associated immune response, the conjugate being obtainable by reacting the carboxyl group-containing organic compound and albumin in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbonyldiimide as activating reagent.
2. (Original): The use as claimed in claim 1 for producing a pharmaceutical for preventing a transplantation-associated immune response.
3. (Currently amended): The use as claimed in claim 1 or 2 for producing a pharmaceutical for the prophylaxis or/and treatment of GVHD (graft versus host disease).
4. (Original): The use as claimed in claim 3, characterized in that GVHD is an acute GVHD.
5. (Original): The use as claimed in claim 3, characterized in that GVHD is a chronic GVHD.
6. (Currently amended): The use as claimed in ~~claim 1-any of the preceding claims~~, characterized in that the transplantation is a bone marrow transplantation.
7. (Currently amended): The use as claimed in ~~claim 1-any of claims 1 to 5~~, characterized in that the transplantation is an organ transplantation, in particular a kidney, heart or liver transplantation.

8. (Currently amended): The use as claimed in claim 1-any of the preceding claims, characterized in that the transplantation is an allogeneic transplantation.
9. (Currently amended): The use as claimed in claim 1-any of the preceding claims, characterized in that the carboxyl group-containing organic compound is selected from cytostatics or immunosuppressants.
10. (Currently amended): The use as claimed in claim 1-any of the preceding claims, characterized in that the carboxyl group-containing organic compound is methotrexate or aminopterin and/or N-phthaloyl-L-glutamic acid.
11. (Currently amended): The use as claimed in claim 1-any of the preceding claims, characterized in that the carboxyl group-containing compound:albumin molar ratio is from 10:1 to 1:10, in particular 1.5:1 to 1:1.5.
12. (Currently amended): The use as claimed in claim 1-any of the preceding claims, characterized in that the albumin is human albumin.
13. (Currently amended): The use as claimed in claim 1-any of the preceding claims, characterized in that the albumin is a native human albumin.
14. (Currently amended): The use as claimed in claim 1-any of the preceding claims, characterized in that the conjugate is a methotrexate-albumin conjugate.
15. (Original): A method for preparing a conjugate comprising:
 - i) a carboxyl group-containing organic compound and
 - ii) albumin,

characterized in that a carboxyl group-containing organic compound and albumin are reacted in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbonyldiimide as activating reagent.

16. (Original): The method as claimed in claim 15, characterized in that the carboxyl group-containing organic compound is a cytostatic or an immunosuppressant.
17. (Currently amended): The method as claimed in claim 15-~~or 16~~, characterized in that the carboxyl group-containing organic compound is methotrexate, aminopterin and/or N-phthaloyl-L-glutamic acid.
18. (Original): The method as claimed in claim 17, characterized in that the carboxyl group-containing organic compound is methotrexate.
19. (Original): The method as claimed in claim 18, characterized in that the carboxyl group-containing compound:albumin molar ratio is from 10:1 to 1:10, in particular 1.5:1 to 1:1.5.
20. (Currently amended): The method as claimed in ~~claim 15-any of claims 15 to 19~~, characterized in that the carboxyl group-containing organic compound is reacted in an organic solvent, in particular in an anhydrous organic solvent, with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, is activated by heating and then the activated carboxyl group-containing organic compound is reacted with the protein.